ClinicalTrials.gg
Not yet recruitingNCT07754682PREV-CARTUpdated Aug 10, 2026

Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma

A Phase 3 interventional study of Immunoglobulin and antibiotic prophylaxis in Chimeric Antigen Receptor T-cell Therapy, B Cell Acute Lymphoblastic Leukemia (B-ALL) and B Cell Lymphoma, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Study summary

B cell (CD19) targeted chimeric antigen receptor modified T Cells (CAR-T) has transformed treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) or B-cell lymphoma (BCL).

Because patients receiving CAR-T often present uncontrolled disease and have undergone several lines of treatment, they may be deeply immuno-depressed and prone to infections. Hypogammaglobulinemia were reported in 74% of patients preCAR-T cells infusion (Hill JA, et al. Blood Rev. 2019 Nov). CART cells also results in depletion of normal CD19+ B cells and hypogammaglobulinemia as an on-target, off tumor toxicity.

Because CAR-T cells can persist for years, patients are exposed to infectious complications secondary to long-term Bcell aplasia and severe hypogammaglobulinemia (\<4g/l). Data from patients who received rituximab (CD20-specific monoclonal antibody) show that patients with severe hypogammaglobulinemia experienced recurrent bronchitis, sinusitis, pneumonia, and rarely, enteroviral meningoencephalitis. In patients receiving CAR T-cells, infection density is 0.55-0.67 infections/100 days3,5 at risk after the first month with a majority of respiratory and ENT (earsnose-throat) infections. To prevent infections, anti-bacterial prophylaxis (AP) based on local guidelines is often used in patients treated by CAR-T cells, with the risk of subsequent resistance. Otherwise, intravenous immunoglobulin replacement therapy (IgRT) is authorized by the French authorities for patients with secondary antibody deficiencies who developed severe or recurrent infections after appropriate antimicrobial therapy, if IgG levels \<4g/l. However, although IgRT as primary prophylaxis (PP) have no approval, they are used as PP after CAR T-cells by many centers, with no data supporting such a strategy. The benefit of IgRT over AP as a primary prophylaxis in the setting of CD19 CAR-T cells therapy should be demonstrated given its burden for patients and care, as well as its cost and the risk of Ig shortage. Therefore, this multi-centric prospective randomized openlabel study aims to assess the benefits of IgRT versus AP as PP in patients with secondary antibody deficiencies.

02

Conditions studied

  • Chimeric Antigen Receptor T-cell Therapy
  • B Cell Acute Lymphoblastic Leukemia (B-ALL)
  • B Cell Lymphoma
  • Antibiotic Prophylaxis
  • Immunoglobulin Therapy
03

In context

Burkitt Lymphoma

977 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

This study's planned enrollment of 228 is above the median of 36 across 766 interventional studies indexed under Burkitt Lymphoma.

Browse Burkitt Lymphoma studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,596 studies on the registry; 1,037 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 16-80 years at inclusion
  2. B-cell acute lymphoblastic leukemia or a B-cell lymphoma
  3. With gamma globulins \<4g/L at the time of screening
  4. Receiving CD19-targeted autologous CAR-T cells (with AMM in their indication)
  5. Patients with * should have reliable for the all duration of the study and another 12 months after CAR-T infusion.
  6. Contraceptive measures for concerned patients
  7. signed by patient or legal representatives

Exclusion criteria

Exclusion Criteria:

  1. Any medical history of intolerance to intravenous immunoglobulin
  2. With renal failure calculated glomerular filtrate rate \<30 mL / min;
  3. With hepatic failure or hepatitis or > 3 times the , Serum /AST >=5N
  4. With existing serious acute infection
  5. to immunoglobulin or to prophylactic antibiotherapy administered in this clinical trial
  6. No health insurance coverage
  7. Females who are pregnant or breastfeeding
  8. Participation in another interventional study or being
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
228 participants (estimated)

Study arms

  • Experimental
    Immunoglobulin Replacement therapy

    Drug: Immunoglobulin

  • Active comparator
    Antibiotic prophylaxis

    Drug: antibiotic prophylaxis

Interventions

  • IgRT 0.4g/Kg IV every 4 weeks for 12 months

  • Drugantibiotic prophylaxis

    PA following each center's guidelines, for 12 months

06

What researchers measure

Primary outcomes

  1. Occurrence of recurrent infections

    Defined by at least 2 episodes requiring a curative systemic antibiotic treatment

    Time frame: At 12 months

  2. Occurrence of a severe infection

    Defined by the need of hospitalization

    Time frame: At 12 months

Secondary outcomes

  1. Cumulative hazard of severe infections

    requiring hospitalization

    Time frame: Up to 12 months

  2. Infection-free survival rate

    Time frame: Up to 12 months

  3. Occurrence of COVID19 infection

    Time frame: Up to 12 months

  4. Cumulative incidence of readmissions due to infectious episode after hospital discharge following the infusion of CART cells

    Time frame: Up to 12 months

  5. Incidence of adverse events due to IgRT and/or PA

    Time frame: Up to 12 months

  6. Dosage of immune markers

    IgA, IgG, IgM, CD19/CD4/CD8 lymphocytes counts, at lymphodepletion

    Time frame: Up to 12 months

  7. Dosage of immune markers

    IgA, IgG, IgM, CD19/CD4/CD8 lymphocytes counts

    Time frame: At 1 month

  8. Dosage of immune markers

    IgA, IgG, IgM, CD19/CD4/CD8 lymphocytes counts

    Time frame: At 3 months

  9. Dosage of immune markers

    IgA, IgG, IgM, CD19/CD4/CD8 lymphocytes counts

    Time frame: At 6 months

  10. Dosage of immune markers

    IgA, IgG, IgM, CD19/CD4/CD8 lymphocytes counts

    Time frame: At 9 months

  11. Dosage of immune markers

    IgA, IgG, IgM, CD19/CD4/CD8 lymphocytes counts

    Time frame: At 12 months

  12. Quality of life assessment

    EQ5D5L : standardized measure of health-related quality of life assessing five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L index score typically ranges from values below 0 (health states considered worse than death) to 1.0 (full health), depending on the country-specific value set. Higher scores indicate better health-related quality of life.

    Time frame: At 3 months

  13. Quality of life assessment

    EQ5D5L : standardized measure of health-related quality of life assessing five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L index score typically ranges from values below 0 (health states considered worse than death) to 1.0 (full health), depending on the country-specific value set. Higher scores indicate better health-related quality of life.

    Time frame: At 6 months

  14. Quality of life assessment

    EQ5D5L : standardized measure of health-related quality of life assessing five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L index score typically ranges from values below 0 (health states considered worse than death) to 1.0 (full health), depending on the country-specific value set. Higher scores indicate better health-related quality of life.

    Time frame: At 9 months

  15. Quality of life assessment

    EQ5D5L : standardized measure of health-related quality of life assessing five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L index score typically ranges from values below 0 (health states considered worse than death) to 1.0 (full health), depending on the country-specific value set. Higher scores indicate better health-related quality of life.

    Time frame: At 12 months

  16. Quality of life assessment

    EORTC QLQ-C30 : cancer-specific questionnaire designed to assess health-related quality of life in patients with cancer. Scores are linearly transformed to a 0-100 scale. For the Global Health Status/Quality of Life scale and the functional scales, higher scores indicate better quality of life and functioning. For symptom scales, higher scores indicate greater symptom burden and poorer health status.

    Time frame: At 3 months

  17. Quality of life assessment

    EORTC QLQ-C30 : cancer-specific questionnaire designed to assess health-related quality of life in patients with cancer. Scores are linearly transformed to a 0-100 scale. For the Global Health Status/Quality of Life scale and the functional scales, higher scores indicate better quality of life and functioning. For symptom scales, higher scores indicate greater symptom burden and poorer health status.

    Time frame: At 6 months

  18. Quality of life assessment

    EORTC QLQ-C30 : cancer-specific questionnaire designed to assess health-related quality of life in patients with cancer. Scores are linearly transformed to a 0-100 scale. For the Global Health Status/Quality of Life scale and the functional scales, higher scores indicate better quality of life and functioning. For symptom scales, higher scores indicate greater symptom burden and poorer health status.

    Time frame: At 9 months

  19. Quality of life assessment

    EORTC QLQ-C30 : cancer-specific questionnaire designed to assess health-related quality of life in patients with cancer. Scores are linearly transformed to a 0-100 scale. For the Global Health Status/Quality of Life scale and the functional scales, higher scores indicate better quality of life and functioning. For symptom scales, higher scores indicate greater symptom burden and poorer health status.

    Time frame: At 12 months

  20. Incremental Cost-Effectiveness Ratio (ICER)

    Time frame: Up to 12 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2029, 36 months later.

Of 19 phase 3 interventional studies under Burkitt Lymphoma, half reached primary completion within 106 months of starting (the median), counting those still running; a quarter within 78 and three quarters within 119. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2026
First posted
Aug 10, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Sep 1, 2029
CompletionEst.
Sep 1, 2029
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07754682
Responsible party
Sponsor
First posted
Aug 10, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 1, 2029 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Aug 10, 2026

Study contacts

Florence Rabian, MD
Contact
florence.rabian@aphp.fr
+33 1 42 38 51 27 ext. +33
Jérôme Lambert, MD PhD
Contact
jerome.lambert@u-paris.fr
+33 1 42 49 97 42 ext. +33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins

Start the discussion